Business, energy, technology, markets and global industry news from Business News Today

Viridian Therapeutics

PharmaDeviceNews Viridian Therapeutics
Dr. Raymond Douglas, MD, PhD, served as principal investigator in the international Tepezza trials that supported its FDA approval.
Features & Analysis

Dr. Raymond Douglas weighs Amgen’s Tepezza as Viridian’s Lumvoa widens TED choices

Amgen’s Tepezza is facing a broader thyroid eye disease treatment landscape after Viridian Therapeutics’ Lumvoa became another approved option, shifting attention toward how physicians may weigh evidence, safety, treatment burden and patient fit. Dr. Raymond Douglas, MD, PhD, who served as principal investigator in the international Tepezza trials that supported its United States Food and

Read More
Viridian Therapeutics’ FDA-approved Lumvoa enters the thyroid eye disease market with a five-infusion treatment course, intensifying competition with Tepezza. Representative image.
Pharma & Biotech

FDA approves Lumvoa for thyroid eye disease as Viridian enters commercial biotech

See how Lumvoa’s FDA approval could reshape thyroid eye disease treatment, challenge Tepezza and test Viridian’s launch strategy.

Read More
Representative image of an ophthalmology exam setting as Minghui Pharmaceutical’s MHB018A data sharpen interest in subcutaneous IGF-1R antibody therapy for thyroid eye disease.
Pharma & Biotech

Can Minghui Pharmaceutical’s MHB018A challenge established thyroid eye disease therapies?

Find out how Minghui Pharmaceutical’s MHB018A could reshape thyroid eye disease treatment as Phase III trials test its promise.

Read More
Pharma & Biotech

Viridian Therapeutics financing puts thyroid eye disease expansion strategy in sharper focus

Viridian has TED trial wins, but market entry needs capital. See why its $350m raise matters before commercialization.

Read More